JP2006510667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510667A5 JP2006510667A5 JP2004559310A JP2004559310A JP2006510667A5 JP 2006510667 A5 JP2006510667 A5 JP 2006510667A5 JP 2004559310 A JP2004559310 A JP 2004559310A JP 2004559310 A JP2004559310 A JP 2004559310A JP 2006510667 A5 JP2006510667 A5 JP 2006510667A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- dendritic cells
- dendritic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 dendritic cell Anatomy 0.000 description 202
- 206010028980 Neoplasm Diseases 0.000 description 110
- 210000004027 cell Anatomy 0.000 description 81
- 239000002243 precursor Substances 0.000 description 47
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 35
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 35
- 238000000034 method Methods 0.000 description 34
- 239000000427 antigen Substances 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 27
- 230000035800 maturation Effects 0.000 description 26
- 239000000758 substrate Substances 0.000 description 26
- 210000000265 leukocyte Anatomy 0.000 description 16
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000001616 monocyte Anatomy 0.000 description 11
- 102000004388 Interleukin-4 Human genes 0.000 description 10
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 229940028885 interleukin-4 Drugs 0.000 description 10
- 230000002601 intratumoral effect Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 239000003104 tissue culture media Substances 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000001464 adherent effect Effects 0.000 description 8
- 230000004041 dendritic cell maturation Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 108020000411 Toll-like receptor Proteins 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001506 immunosuppresive effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 102000003816 Interleukin-13 Human genes 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000009295 crossflow filtration Methods 0.000 description 5
- 238000005138 cryopreservation Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 229940124669 imidazoquinoline Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 102100035793 CD83 antigen Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 4
- 102100022297 Integrin alpha-X Human genes 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229940100994 interleukin-7 Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- RXNTZIJLOZMJTM-UHFFFAOYSA-N 2-(2h-quinolin-1-yl)ethanol Chemical compound C1=CC=C2N(CCO)CC=CC2=C1 RXNTZIJLOZMJTM-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical group OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- -1 imidazoquinoline compound Chemical class 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 2
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 2
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000000315 cryotherapy Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000554 metrizamide Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- STDHLKOFRZEOGS-UHFFFAOYSA-N 5h-imidazo[4,5-h]quinolin-4-amine Chemical class C12=NC=CC=C2CC(N)=C2C1=NC=N2 STDHLKOFRZEOGS-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001862 defibrillatory effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43126702P | 2002-12-06 | 2002-12-06 | |
| US60/431,267 | 2002-12-06 | ||
| PCT/US2003/038672 WO2004053072A2 (en) | 2002-12-06 | 2003-12-05 | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011196385A Division JP5707284B2 (ja) | 2002-12-06 | 2011-09-08 | 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006510667A JP2006510667A (ja) | 2006-03-30 |
| JP2006510667A5 true JP2006510667A5 (enExample) | 2007-01-25 |
| JP4859169B2 JP4859169B2 (ja) | 2012-01-25 |
Family
ID=32507696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559310A Expired - Lifetime JP4859169B2 (ja) | 2002-12-06 | 2003-12-05 | 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与 |
| JP2011196385A Expired - Fee Related JP5707284B2 (ja) | 2002-12-06 | 2011-09-08 | 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011196385A Expired - Fee Related JP5707284B2 (ja) | 2002-12-06 | 2011-09-08 | 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20060057120A1 (enExample) |
| EP (2) | EP2260861A1 (enExample) |
| JP (2) | JP4859169B2 (enExample) |
| KR (1) | KR101144196B1 (enExample) |
| CN (2) | CN1738619B (enExample) |
| AT (1) | ATE486125T1 (enExample) |
| AU (2) | AU2003293411B2 (enExample) |
| BR (1) | BRPI0317064B8 (enExample) |
| CA (1) | CA2509058A1 (enExample) |
| DE (1) | DE60334725D1 (enExample) |
| DK (1) | DK1567155T3 (enExample) |
| ES (1) | ES2354944T3 (enExample) |
| IL (1) | IL169002A (enExample) |
| MX (1) | MXPA05006042A (enExample) |
| PL (1) | PL377209A1 (enExample) |
| PT (1) | PT1567155E (enExample) |
| RU (1) | RU2348418C2 (enExample) |
| WO (1) | WO2004053072A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004053072A2 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| US20070134273A1 (en) * | 2004-02-10 | 2007-06-14 | Francois Romagne | Composition and method for the treatment of carcinoma |
| US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
| US8076132B2 (en) | 2004-09-17 | 2011-12-13 | Hasumi International Research Foundation | Dendritic cell tumor injection (DCTI) therapy |
| WO2006095330A2 (en) * | 2005-03-10 | 2006-09-14 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
| WO2007001200A1 (en) * | 2005-06-23 | 2007-01-04 | Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' | Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon |
| AR060424A1 (es) * | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| WO2008133595A1 (en) * | 2007-04-26 | 2008-11-06 | Newbiomed Pika Pte Ltd | Compositions and methods for stimulating an immune response in-vivo and in-vitro |
| WO2008151389A1 (en) * | 2007-06-15 | 2008-12-18 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Chemically modified macromolecules |
| EP2072617A1 (en) * | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
| RU2361598C1 (ru) * | 2008-02-18 | 2009-07-20 | Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) | Средство, индуцирующее созревание дендритных клеток |
| CA3123228A1 (en) * | 2008-03-27 | 2009-10-01 | Asterias Biotherapeutics, Inc. | Differentiation of primate pluripotent stem cells to hematopoietic lineage cells |
| KR101788885B1 (ko) * | 2009-07-09 | 2017-10-20 | 타이제닉스, 에스.에이.유. | 세포 요법에 사용하기 위한 방법 및 조성물 |
| ES2581277T3 (es) * | 2010-02-10 | 2016-09-05 | Immunicum Ab | Composición mejorada para inhibir la proliferación de células tumorales |
| CA2793458A1 (en) * | 2010-03-15 | 2011-09-22 | The Trustees Of The University Of Pennsylvania | System and method of preparing and storing activated mature dendritic cells |
| RU2530523C2 (ru) * | 2012-03-29 | 2014-10-10 | Олег Борисович Егоров | Способ противоопухолевой иммунотерапии |
| SG11201510552WA (en) | 2012-06-27 | 2016-01-28 | Hasumi Internat Res Foundation | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
| GB201300049D0 (en) * | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-stimulatory dendritic cells |
| KR20160093012A (ko) | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| CN114774356A (zh) | 2015-06-30 | 2022-07-22 | 西北生物治疗药物公司 | 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞 |
| WO2017048875A1 (en) * | 2015-09-15 | 2017-03-23 | Northwest Biotherapeutics, Inc | Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers |
| KR101749165B1 (ko) * | 2016-06-07 | 2017-06-23 | 충남대학교산학협력단 | Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 |
| WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
| GB201711379D0 (en) * | 2017-07-14 | 2017-08-30 | Univ Cape Town | Maturation of dendritic cells |
| CN109957548B (zh) * | 2017-12-26 | 2022-03-18 | 上海尚泰生物技术有限公司 | 一种基因修饰的树突状细胞疫苗 |
| GB2624871A (en) * | 2022-11-29 | 2024-06-05 | Alv B As | Process for preparing a population of dendritic cells and immunotherapy using the same |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| DK0633929T3 (da) | 1992-04-01 | 2004-06-28 | Univ Rockefeller | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener |
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| ATE428769T1 (de) * | 1997-10-27 | 2009-05-15 | Univ Rockefeller | Methode und zusammensetzung zur herstellung von reifen dendritischen zellen |
| US6797488B1 (en) * | 1997-12-08 | 2004-09-28 | Beth Israel Deaconess Medical Center | Methods of producing anti-angiogenic proteins |
| AU6144499A (en) * | 1998-09-15 | 2000-04-03 | University Of Pittsburgh | In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression |
| CN1321189A (zh) * | 1998-10-02 | 2001-11-07 | 三菱化学株式会社 | 细胞性免疫的诱导方法以及被诱导了细胞免疫的细胞 |
| US6649158B1 (en) * | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| JP2002541195A (ja) * | 1999-04-14 | 2002-12-03 | アメリカ合衆国 | 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物 |
| WO2001048154A1 (en) * | 1999-12-28 | 2001-07-05 | Toyoshima, Kumao | Maturation-promoting agent for immature dendritic cells |
| JP4841794B2 (ja) * | 2000-05-12 | 2011-12-21 | ノースウエスト バイオセラピューティクス，インコーポレイティド | ヒト樹状細胞による外因性抗原のクラスｉ提示を増加させる方法 |
| JP2002069001A (ja) * | 2000-08-29 | 2002-03-08 | Asahi Kasei Corp | 樹状細胞を主成分とする細胞ワクチン |
| AU2002224851A1 (en) * | 2000-11-14 | 2002-05-27 | Universite Libre De Bruxelles | Generation and use of dendritic cells |
| US20020094545A1 (en) | 2000-11-30 | 2002-07-18 | Harris Paul E. | Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads |
| WO2003010292A2 (en) * | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| EP2322603B1 (en) * | 2001-09-06 | 2019-10-16 | NorthWest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| WO2004053072A2 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| DK1604016T3 (da) * | 2003-02-27 | 2009-05-18 | Northwest Biotherapeutics Inc | In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler |
-
2003
- 2003-12-05 WO PCT/US2003/038672 patent/WO2004053072A2/en not_active Ceased
- 2003-12-05 MX MXPA05006042A patent/MXPA05006042A/es active IP Right Grant
- 2003-12-05 RU RU2005121256/14A patent/RU2348418C2/ru active IP Right Revival
- 2003-12-05 ES ES03790358T patent/ES2354944T3/es not_active Expired - Lifetime
- 2003-12-05 EP EP20100176476 patent/EP2260861A1/en not_active Ceased
- 2003-12-05 CN CN2003801089756A patent/CN1738619B/zh not_active Expired - Fee Related
- 2003-12-05 DE DE60334725T patent/DE60334725D1/de not_active Expired - Lifetime
- 2003-12-05 PL PL377209A patent/PL377209A1/pl not_active Application Discontinuation
- 2003-12-05 CN CN201210027703.4A patent/CN102600461B/zh not_active Expired - Fee Related
- 2003-12-05 AT AT03790358T patent/ATE486125T1/de active
- 2003-12-05 DK DK03790358.0T patent/DK1567155T3/da active
- 2003-12-05 PT PT03790358T patent/PT1567155E/pt unknown
- 2003-12-05 BR BRPI0317064A patent/BRPI0317064B8/pt not_active IP Right Cessation
- 2003-12-05 KR KR1020057010303A patent/KR101144196B1/ko not_active Expired - Fee Related
- 2003-12-05 US US10/538,226 patent/US20060057120A1/en not_active Abandoned
- 2003-12-05 AU AU2003293411A patent/AU2003293411B2/en not_active Ceased
- 2003-12-05 EP EP03790358A patent/EP1567155B1/en not_active Expired - Lifetime
- 2003-12-05 JP JP2004559310A patent/JP4859169B2/ja not_active Expired - Lifetime
- 2003-12-05 CA CA002509058A patent/CA2509058A1/en not_active Expired - Lifetime
-
2005
- 2005-06-05 IL IL169002A patent/IL169002A/en active IP Right Grant
-
2011
- 2011-01-28 AU AU2011200352A patent/AU2011200352B2/en not_active Ceased
- 2011-09-08 JP JP2011196385A patent/JP5707284B2/ja not_active Expired - Fee Related
-
2012
- 2012-06-04 US US13/488,388 patent/US20120251561A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5707284B2 (ja) | 腫瘍の処置のための、インビトロでの部分的に成熟した樹状細胞の投与 | |
| JP2006510667A5 (enExample) | ||
| US20220145246A1 (en) | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response | |
| AU2018260971B2 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
| AU2013234394B2 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
| HK40077476A (en) | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response | |
| HK1151249A (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
| HK1082180B (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors |